Evidence map›Paper›PMID 40959947›Full record

ArticlePalliative & supportive care2025

Benefits of duloxetine may outweigh risks in a patient with hormone-positive breast cancer.

Gustavo Scannapieco Mastroleo, Kayley Ancy, Akhila Reddy

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Palliative & supportive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gustavo Scannapieco MastroleoDepartment of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0009-0004-6619-866X
Kayley AncyDepartment of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0009-0005-3059-3083
Akhila ReddyDepartment of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-7628-8675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDuloxetine is the only agent for chemotherapy-induced peripheral neuropathy (CIPN) recommended by the American Society of Clinical Oncology. As a moderate inhibitor of cytochrome P450 isoenzyme 2D6, duloxetine is theorized to decrease the efficacy of tamoxifen, which may be used to treat estrogen receptor-positive breast cancer. A case prompted our team to review the literature to elucidate the risks and benefits of duloxetine use in patients with this cancer.

methodsWe present the case of a patient with estrogen receptor-positive breast cancer who was doing well on duloxetine for CIPN. Due to concern for the possible future need for tamoxifen, she was switched to multiple other agents, including venlafaxine, without success.

resultsUltimately, the patient was switched back to duloxetine due to persistent CIPN symptoms. The theoretical risk of tamoxifen interaction with duloxetine has not been demonstrated to be clinically significant in the literature. SIGNIFICANCE OF

resultsWhile emerging evidence suggests venlafaxine may prove an effective alternative, duloxetine remains the agent with the strongest evidence of benefit in patients with CIPN and must remain an option in this patient population.

Indexed as

Breast NeoplasmsDuloxetine HydrochloridePeripheral Nervous System DiseasesAdultFemaleHumansSerotonin and Noradrenaline Reuptake InhibitorsTamoxifenVenlafaxine HydrochlorideDuloxetine HydrochlorideSerotonin and Noradrenaline Reuptake InhibitorsTamoxifenVenlafaxine Hydrochloridechemotherapy-induced peripheral neuropathyDuloxetinehormone-positive breast cancerpalliative careserotonin-norepinephrine reuptake inhibitorssupportive caretamoxifen

Identifiers

PMID40959947
PMCPMC13166437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.